Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.
Saved in:
| Title: | Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants. |
|---|---|
| Authors: | Bajoria S; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA., Kaur K; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA., Kumru OS; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA., Van Slyke G; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA., Doering J; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA., Novak H; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA., Rodriguez Aponte SA; Department of Biological Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.; The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Dalvie NC; The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Chemical Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA., Naranjo CA; The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Johnston RS; The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Silverman JM; Bill & Melinda Gates Foundation, Seattle, WA, USA., Kleanthous H; Bill & Melinda Gates Foundation, Seattle, WA, USA., Love JC; The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.; Department of Chemical Engineering, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA., Mantis NJ; Division of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA., Joshi SB; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA., Volkin DB; Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA. |
| Source: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Nov 30; Vol. 18 (5), pp. 2079346. Date of Electronic Publication: 2022 Jun 06. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2164-554X |
|---|---|
| DOI: | 10.1080/21645515.2022.2079346 |
